🧬 Early results for GLM101 in #PMM2CDG:
3 adults treated for 24 weeks showed a mean 17.7-point improvement in ICARS, with improvement across all ataxia domains and no serious adverse events.
Small, open-label study — but an encouraging signal.
doi.org/10.1002/jimd...
#JIMD #CDG
3 adults treated for 24 weeks showed a mean 17.7-point improvement in ICARS, with improvement across all ataxia domains and no serious adverse events.
Small, open-label study — but an encouraging signal.
doi.org/10.1002/jimd...
#JIMD #CDG
September 12, 2026 at 5:58 AM
🧬 Early results for GLM101 in #PMM2CDG:
3 adults treated for 24 weeks showed a mean 17.7-point improvement in ICARS, with improvement across all ataxia domains and no serious adverse events.
Small, open-label study — but an encouraging signal.
doi.org/10.1002/jimd...
#JIMD #CDG
3 adults treated for 24 weeks showed a mean 17.7-point improvement in ICARS, with improvement across all ataxia domains and no serious adverse events.
Small, open-label study — but an encouraging signal.
doi.org/10.1002/jimd...
#JIMD #CDG